Does hepatic insulin resistance raise fasting glucose and triglycerides?

Hepatic insulin resistance is a key metabolic driver where the liver fails to respond to insulin's regulatory signals, disrupting systemic glucose and lipid homeostasis.

Mechanistic pathways

• Loss of FoxO1 Regulation: In healthy states, insulin signaling via the IR-IRS-PI3K-Akt cascade phosphorylates the transcription factor FoxO1, causing its nuclear exclusion. In insulin-resistant states, impaired Akt activation leaves FoxO1 active in the nucleus.
• Unsuppressed Glucose Output: Persistent nuclear FoxO1 drives the transcription of rate-limiting gluconeogenic enzymes, specifically phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), preventing the suppression of hepatic glucose output.
• Accelerated VLDL Assembly: Active nuclear FoxO1 upregulates microsomal triglyceride transfer protein (MTP) expression, promoting apolipoprotein B (apoB) lipidation and VLDL assembly. Concurrently, SREBP-1c-mediated de novo lipogenesis remains active, supplying ample lipid substrates to assemble and secrete large, triglyceride-rich VLDL1 particles.

Clinical evidence and temporal progression

• Metabolic Dysregulation: Hyperinsulinemic-euglycemic clamp and tracer kinetics studies demonstrate that insulin fails to suppress hepatic glucose and VLDL-triglyceride output in resistant individuals.
• Sequential Manifestation: Clinical evidence indicates that impaired suppression of VLDL secretion often occurs early in metabolic dysfunction, preceding the loss of control over hepatic glucose output. Over time, both pathways fail, presenting clinically as above-optimal fasting glucose and elevated triglycerides.

Bottom line

• Hepatic insulin resistance directly prevents insulin from suppressing both hepatic glucose output and VLDL triglyceride secretion via impaired Akt-FoxO1 signaling, leading to elevated fasting glucose and fasting triglycerides.